PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure
PD-1-Inhibitor-induzierte rheumatische, endokrine und sarkoidoseähnliche immunvermittelte Nebenwirkungen bei metastasiertem Melanom sind mit besserem Überleben und geringerer Kortikosteroid-Exposition verbunden
Immunotherapy Advances · 31.12.2025 · 6 (1)
DOI: 10.1093/immadv/ltag004 ↗Auf einen Blick
Bei 301 Patient:innen mit fortgeschrittenem kutanem Melanom war das Gesamtüberleben bei irAE länger. Rheumatische, endokrine und sarkoidoseähnliche irAE waren mit besserem Überleben verbunden.
Fragestellung
Sind bestimmte PD-1-Inhibitor-induzierte irAE bei metastasiertem Melanom mit dem Überleben und der Kortikosteroid-Exposition assoziiert?
Methode
Retrospektive Kohortenstudie über 7 Jahre bei 301 Patient:innen mit fortgeschrittenem kutanem Melanom unter PD-1-Monotherapie; Auswertung mit Kaplan-Meier- und Cox-Modellen, inkl. zeitabhängiger Analysen.
Ergebnisse
109 von 301 Patient:innen hatten irAE. Rheumatische irAE und späte Schilddrüsen-irAE blieben nach Adjustierung mit verbessertem OS assoziiert. Sarkoidoseähnliche und Hypophysitis-irAE waren selten, aber mit exzellenten Outcomes verbunden.
Schlussfolgerung der Autor:innen
Rheumatische, endokrine und sarkoidoseähnliche irAE sind Marker für ein besseres Überleben; niedrigere initiale Kortikosteroiddosen könnten die Wirksamkeit von PD-1-Inhibitoren erhalten.
Kernaussagen
- 109 von 301 Patient:innen hatten irAE
- Rheumatische und späte Schilddrüsen-irAE: besseres OS
- Niedrigere Startdosen von Kortikosteroiden bei den meisten überlebensassoziierten irAE
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 21.02.2026. Verfasst von Maria Lindén und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Vetenskapsrådet, Swedish Cancer Foundation.
Themen: Patientensicherheit
Abstract (Originalsprache)
Introduction
Programmed cell death protein 1 (PD-1) inhibitors improve survival in advanced melanoma but can induce immune-related adverse events (irAEs). IrAEs have been linked to better outcomes. However, it remains unclear whether specific irAE types drive this effect and how corticosteroid treatment of irAEs influences survival. Materials and methods A seven-year retrospective cohort study of 301 patients with advanced cutaneous melanoma treated with single-agent PD-1 inhibition at Sahlgrenska University Hospital. irAEs were identified using CTCAE v4.0/v5.0, and irAEs requiring systemic corticosteroids or endocrine replacement therapy were included. Corticosteroid therapy was categorized as low dose (≤0.5 mg/kg prednisolone equivalent) or high dose (>0.5 mg/kg). Overall survival (OS) was assessed using Kaplan–Meier and Cox models, including time-dependent analyses to address immortal time bias.
Results
Patients with irAE (109 of 301 patients) had longer OS than those without irAEs. Of the eight most common irAEs, four were associated with superior survival, one was borderline significant, and three were non-significant. Rheumatic irAEs and late-onset thyroid irAEs remained associated with improved OS after adjustment for negative prognostic factors and immoral time bias. Colitis irAE were borderline significant in univariate analysis. Sarcoidosis-like and hypophysitis irAEs were rare but conferred excellent outcomes. Hepatitis, nephritis, and pneumonitis were not associated with better survival. Most survival-associated irAEs were treated with a lower start dose of corticosteroids but duration and time to onset were similar to non–survival-associated irAEs.
Conclusion
Rheumatic, endocrine, and sarcoidosis-like irAEs are markers of superior survival and suggest that lower initial corticosteroid doses may preserve PD-1 inhibitor efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
ORCID-Profile: Anna Fager, Anna Rudin, Max Levin
Förderung
- Swedish Research Council
- Vetenskapsrådet
- Swedish Cancer Foundation
- Cancerfonden
- Jubileumsklinikens Cancerfond
- Lions Cancerfond Väst
- Castenbäcks stiftelse
- Stiftelsen Assar Gabrielssons Fond
Zitieren
APA
Lindén, M., Al Remawi, H., Fager, A., Akyürek, L. M., Rudin, A., Ny, L., Bjursten, S., Pandita, A., & Levin, M. (2025). PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag004
Vancouver
Lindén M, Al Remawi H, Fager A, Akyürek LM, Rudin A, Ny L, et al. PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag004
BibTeX
@article{Lindn2025,
author = {Lindén, Maria and Al Remawi, Hifaa and Fager, Anna and Akyürek, Levent M and Rudin, Anna and Ny, Lars and Bjursten, Sara and Pandita, Ankur and Levin, Max},
title = {PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure},
journal = {Immunotherapy Advances},
year = {2025},
volume = {6},
number = {1},
doi = {10.1093/immadv/ltag004}
}
EUVIMED